SG/CALL/MODERNA/140/0.1/21.06.24 | Delayed Deutsche Boerse AG 08:04:55 13/05/2024 pm IST | ||
| 0.26 EUR | +52.94% |
|
| Current month | -22.73% | ||
| 1 month | -26.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 0.26 | +52.94% | 0 |
| 10/24/10 | 0.17 | -37.04% | 0 |
| 09/24/09 | 0.27 | +12.50% | 0 |
| 08/24/08 | 0.24 | 0.00% | 0 |
| 07/24/07 | 0.24 | -4.00% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 13, 2024 at 08:04 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ80AS |
| ISIN | DE000SQ80AS7 |
| Date issued | 13/02/2023 |
| Strike | 140 $ |
| Maturity | 21/06/2024 (39 Days) |
| Parity | 10 : 1 |
| Emission price | 5.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.29 € |
|---|---|
| Lowest since issue | 0.12 € |
| Spread | 0.01 € |
| Spread % | 3.70% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
- Stock Market
- Warrants
- Warrant